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Abstract
Background: Nephritis is the most important chronic complication of IgA Vasculitis (IgAV)/Henoch-Schönlein
purpura (IGAV/HSP) and thus the main prognostic factor of this most common childhood vasculitis. Since the
prognosis and treatment selection depends on the mode of interpretation of biopsy material, in this manuscript we
have presented several issues related to the uneven application of different histological classifications in IgAV/Henoch-
Schönlein purpura nephritis (HSPN). The nephritis of IgAV/IGAV/HSP will be abbreviated as HSPN for this paper.
Main body: In clinical practice we use different histological classifications for HSPN. It is not known which of these
classifications best correlates with severity of renal disease and renal outcome in IgAV/IGAV/HSP. One of the major
problem with existing histological classifications is that there is no consensus on the implementation of biopsy in the
treatment of HSPN. There is a histologic classification system conventionally used in HSPN, of the International Study of
Kidney Disease in Children (ISKDC). On the other hand there is the new classification system suggested for IgA
nephropathy, the Oxford classification. The latter has been validated only in IgA nephropathy. There are also two
further histologic classifications of Haas and Koskela that have been developed. Current treatment strategies in HSPN
are not standardised nor predominantly based on histological classification.
Conclusion: One of the possible solutions to problems related to the application of different histological classification
in HSPN is the implementation of multicenter multinational prospective studies with joint collaboration between pediatric
rheumatologists, nephrologists and nephropathologists to correlate the clinical features and outcome with the classification
systems as well among the classifications. This classification should be the basis for the construction of guidelines for the
treatment of patients with HSPN.
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Background
Henoch-Schönlein purpura (IGAV/HSP) or IgA vascu-
litis (IgAV) is the most frequent form of vasculitis in
childhood, with an annual incidence of 13–20/100000
children under 17 years of age [1, 2]. The European League
Against Rheumatism (EULAR), Paediatric Rheumatology
International Trials Organization (PRINTO) and Paediatric
Rheumatology European Society (PRES) (EULAR/PRI
NTO/PRES) defined the criteria for diagnosis of IgAV/
IGAV/HSP [3].
Although the disease is typically self-limiting and the
prognosis is largely good [4], renal involvement may
advance and cause permanent organ damage in the form
of severe nephritis (HSPN) [5] making the renal involve-
ment of the disease the main prognostic factor [6, 7].
Since the confirmation of diagnosis of HSPN requires a
biopsy of the kidneys, and histological classification of the
obtained material has an important role to determine prog-
nosis and therapy selection, in this review article we aim to
describe existing problems related to the commonly used
histological classifications for predicting outcome in HSPN.* Correspondence: marija.jelusic@mef.hr
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Main text
Renal manifestations in IGAV/HSP
Renal involvement occurs in a variable proportion (20–
60%) of children suffering from IGAV/HSP [2, 7, 8]. Vast
majority of children with IGAV/HSP (97%) develop
features of renal involvement within 6months of disease
onset, but sometimes HSPN may occur later [7, 9–11].
The renal disease spectrum ranges from urinary abnormal-
ities (including hematuria or/and proteinuria) through
nephritic and nephrotic syndrome to chronic renal failure.
Renal involvement is typically mild and manifested only by
pathological urine findings. The greatest number of pa-
tients with HSPN, about 50% of them, develop simultan-
eous hematuria and proteinuria [9, 12]. Nephritic or
nephrotic syndrome occurs in about 20% of HSPN patients
[9, 12]. Chronic renal failure in children was noted to occur
in a wide range of proportions of patients, from 1 to 15%
[7, 9, 13, 14]. Patients with both nephritic and nephrotic
syndrome have the highest risk for progression to end-
stage renal disease (ESRD): more than 50% of them will
develop long-term renal impairment, compared to about
5% of patients with urinary abnormalities (hematuria and/
or proteinuria) [9, 12].
Different histological classifications for HSPN
Due to the fact that glomerulonephritis is the major cause
of mortality and morbidity among children suffering from
IGAV/HSP, the prognosis of the disease largely relies on
the renal involvement of IGAV/HSP [6, 9]. A kidney biopsy
is mandatory for the diagnosis of HSPN. However, its value
as a predictor of the outcome is dependent on many
variables, principally on the classification used. Today we
use different histological classifications for HSPN and four
of them, utilized in clinical practice and research studies,
are described below.
The International Study of Kidney Disease in Children
(ISKDC) classification [15, 16] is still the most frequently
used for histological analysis of renal biopsy findings in
HSPN [17] (Table 1). The basic morphological changes
underlying to a big extent of this classification are
crescents. These lesions, whose pathogenic mechanism of
development is still not elucidated, are associated with
capillary wall destruction due to fibrinoid necrosis, which is
linked with endocapillary proliferation and infiltration of in-
flammatory cells, including macrophages and neutrophils
[18]. According to ISKDC classification, renal biopsies can
be categorized into one of six histological grades. The first
five grades of histological lesions are based on the presence
and number of crescents. Grade VI represents membrano-
proliferative like glomerulonephritis, characterized with
changes in the mesangial elements and the glomerular
capillary wall. Crescents seemed a promising prognostic
factor according to earlier studies, but in later publications
the correlation between crescents and outcome has not
always been confirmed [10, 19–21]. Namely, studies have
shown that even patients with low grade histologic lesions,
in the absence of crescents, may develop chronic renal
failure and that patients with higher histological stages may
experience spontaneous healing of lesions [10, 20, 21].
Unfortunately this grading system, being grounded mostly
on the state of glomeruli, only reflects active inflammation,
in the same time neglecting vascular and tubulointerstitial
changes [19, 22].
It was subsequently shown that the proportion of scler-
otic glomeruli and interstitial fibrosis correlates better with
the long-term outcome, leading to the idea that the Oxford
classification, used in IgA nephropathy, could be used in
predicting the progression of renal disease in HSPN [23–
25]. This scoring system published in 2009 initially included
four morphologic features: mesangial hypercellularity (M),
endocapillary proliferation (E), segmental glomerulosclero-
sis/adhesion (S) and tubular atrophy/interstitial fibrosis (T)
[26, 27]. These four parameters formed the MEST score.
Crescents were not included in the first version of the clas-
sification. The working group has made recommendations
for changes to the Oxford classification in 2016 and has
proposed the addition of a C (crescent score) to MEST as
well as revising the S score, considering the presence or ab-
sence of podocytopathic features (podocyte hypertrophy/tip
lesions). The revised Oxford classification includes
MEST-C score [28] (Table 2). However, the working group
does not recommend the use of MEST-C score in HSPN
since cases of patients with this condition were not
included in the validation cohort.
Histologic classification of IgA nephropathy of Haas is
based on retrospective studies using development of
ESRD as their primary endpoint. Haas reviewed the histo-
logic features of 244 cases of IgA nephropathy and using
this histologic classification found statistically significant
Table 1 The International Study of Kidney Disease in Children
(ISKDC) classification of Henoch-Schönlein purpura nephritis (a
modification according to ref. [16])
ISKDC grade Description
Grade I Minimal alterations
Grade II Mesangial proliferation
Grade III Proliferation or sclerosis
with < 50% crescents ((a)
focal or (b) diffuse)
Grade IV Mesangial proliferation
or sclerosis with 50–75%,
crescents ((a) focal or
(b) diffuse)
Grade V Mesangial proliferation
or sclerosis with > 75%
crescents ((a) focal or (b)
diffuse)
Grade VI Membranoproliferative
like glomerulonephritis
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correlation between IgA subclass and renal survival [29]
(Table 3).
The latest classification, developed by Koskela et al. in
2017., is the modified semiquantitative classification
(SQC). It takes into account no less than 14 variables,
evaluating both, the activity and chronicity components
making it the most precise and most promising so far [30].
Glomerular, tubular, interstitial and vascular findings are
scored and a maximum score is defined as total biopsy
score. The scoring system also includes activity index,
chronicity index, focal or diffuse mesangial proliferation.
Koskela et al. evaluated comparatively the ISKDC and
SQC classifications in a national cohort of paediatric HSPN
patients. Unfortunately, the number of patients in the ori-
ginal study was far too low (53 patients) to properly valid-
ate the classification (Table 4). Although the research
showed promising results, according to which the variables
of SQC (the total biopsy score and activity index) are better
and more sensitive than ISKDC grades in prediction of
patient outcome in HSPN, a study of a greater number of
patients is needed.
Table 5 summarize the most frequently used classifica-
tions for histological analysis of renal biopsy findings in
HSPN in clinical practice around the world. From this table
it is obvious the data about histologic classifications for
HSPN from some parts of the world are scarce with surpris-
ingly very few recent studies. It may be noticed there is a
considerable number of articles in which different modified
or local pathological scoring classification systems are used.
The correlation between clinical aspects and histopatho-
logic findings in HSPN has been the subject of several stud-
ies. Firstly, it was found that the presence, type and number
of glomerular crescents in a biopsy specimen has a large
role in the prognostic process, detecting a poorer outcome
in patients with more than 50% of crescents, which was the
basis for forming the ISKDC classification [5, 9, 31, 32].
However, as noted above, other studies did not confirm this
finding, perhaps due to an uneven distribution of crescents,
too small biopsy specimen, the possibility of spontaneous
healing of histological lesions or the fact that patients with
crescents were treated more aggressively [10, 21, 33, 34].
Tubulointerstitial lesions were found to positively correlate
with a more severe outcome [25, 35, 36]. Furthermore,
chronic lesions alongside acute lesions were identified as
predictors of poor prognosis [34], where the total biopsy
score acquired with the modified SQC differentiated pa-
tients with a score of ≤10 points as patients with a favorable
outcome and with a score of ≥11 as patients with a greater
risk of renal deterioration [30].
What are the problems with the existing classifications of
HSPN?
It is necessary to point out several issues regarding the
existing classifications of HSPN. Of all the classifications
most commonly used in clinical practice as well as for
research purposes, it is not known which one predicts
Table 2 The Oxford classification of IgA nephropathy
(according to ref. [28])
Histological variable Description
Mesangial
hypercellularity
M0 < 50% of glomeruli showing mesangial
hypercellularity
M1 > 50% of glomeruli showing mesangial
hypercellularity
Endocapillary
hypercellularity
E0 absent
E1 present
Segmental
glomerulosclerosis/adhesion
S0 absent
S1 present
presence or absence of podocyte
hypertrophy/tip lesions in biopsies
with S1
Tubular atrophy/interstitial
fibrosis
T0 ≤ 25% of the cortical area affected
by tubular atrophy or interstitial fibrosis
T1 26–50% of the cortical area affected
by tubular atrophy or interstitial fibrosis
T2 > 50% of the cortical area affected
by tubular atrophy or interstitial fibrosis
Cellular/fibrocellular
crescents
C0 absent
C1 present in at least one glomerulus
C2 present in > 25% of glomeruli
Modified with permission from Elsevier Ltd.©
Table 3 Histologic classification of IgA nephropathy of Haas (according to ref. [29])
Haas classification Description
Class I – Minimal histologic lesion Glomeruli are normocellular, without segmental sclerosis, necrosis, or crescents.
Class II – Focal-segmental glomerulosclerosis
(FSGS)-like
Glomeruli show focal and segmental sclerosis without mesangial or endocapillary
hypercellularity, crescents, or necrosis.
Class III – Focal proliferative glomerulonephritis 50% or fewer of the glomeruli (not including globally sclerotic glomeruli) are hypercellular.
This hypercellularity may be limited to mesangial areas, or include endocapillary hypercellularity,
crescents, or necrosis.
Class IV – Diffuse proliferative glomerulonephritis More than 50% of the glomeruli (not including globally sclerotic glomeruli) are hypercellular.
This hypercellularity may be limited to mesangial areas, or include endocapillary hypercellularity,
crescents, or necrosis.
Class V – Advanced chronic glomerulonephritis 40% or more of the glomeruli are globally sclerotic, and/or there is > 40% estimated tubular
atrophy or loss in the cortex. If these criteria are met, the biopsy specimen is graded as class V
regardless of other histologic features.
Modified with permission from Elsevier Ltd.©
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the renal outcome in IGAV/HSP and has the strongest asso-
ciation with unfavorable outcome. There are no studies that
compare all the most frequently used classifications. This
certainly has implications for defining the standardised man-
agement since histology is an important point in deciding
whom to treat and with which medications. Lupus nephritis
is, like HSPN, another inflammatory renal disease, but here
the treatment strategies are based on histological classifica-
tion. This is possible since the classification system in use
is associated with severity of renal disease and renal out-
come [37, 38]. Although the evidence for treatment of
childhood-onset systemic lupus erythematosus and lupus
nephritis is limited and there is a need for further research,
representative rheumatologists and nephrologists managed
to reach a consensus [38].
An important problem of classifications for HSPN is that
they have not been validated in (sufficiently large numbers
of) children or have been validated only in IgA nephropathy.
For example, in the recommendations for updating the Ox-
ford Classification the working group clearly accentuated
the necessity of inclusion of larger number of children to
avoid inadequate statistical power due to the limited number
of patients reaching end points [28]. To date only few stud-
ies compared clinical and histological features between
adults and children with HSPN, and showed that there are
differences between these age groups [39]. Although HSPN
in adults is a rare disease, a recent study showed that renal
pathological chronicity was more serious in adults than in
children: approximately 30% of adults with HSPN develop
chronic renal failure [39, 40].
Findings from research on IgA nephropathy have been ap-
plied also to patients with HSPN. For instance, due to
shared clinical, immunological and histological findings be-
tween the two diseases, it has been suggested that the Ox-
ford classification can be used in classifying HSPN and it
has been used in clinical practice [17, 35, 41–45]. Although
these two diseases share similar features, there are also clini-
copathological differences that are not only the mere pres-
ence of extrarenal clinical signs in IGAV/HSP [12, 22]. The
most important differences in the clinical presentation of
the two diseases are age and clinical signs. While IGAV/
HSP has a peak incidence in the age between 4 and 7 years,
and HSPN is predominantly seen in childhood, this range
for IgA nephropathy is between 15 and 30 years. HSPN
patients more often present as nephrotic or nephritic syn-
drome, whereas in IgA nephropathy such initial presentation
is rare. Furthermore, HSPN frequently has an acute onset
and course while IgA nephropathy is usually chronic pro-
gressive renal disease that gradually leads to renal failure.
The risk of ESRD is higher in children with HSPN than in
children with IgA nephropathy. Histologically, it should be
noted that necrotizing changes and fibrin deposits in the
glomerulus as well as endocapillary proliferation and cres-
cents formation are more common in HSPN than in IgA
nephropathy. Pathohistological changes in IgA nephropathy
are predominantly found in mesangium and gradually lead
to glomerulosclerosis and interstitial fibrosis. The main
mechanisms of damage in HSPN are glomerular endothelial
lesions that may heal or progress to fibrosis with scarring
and chronic kidney damage [22]. Although the similarities
between HSPN and IgA nephropathy are numerous, differ-
ences in clinical manifestation, course of the disease and
renal damage mechanisms raise the question of the efficacy
of uniform treatment of these two conditions and the possi-
bility of a different therapeutic response to the same treat-
ment [22]. Therefore, all classifications for IgA nephropathy
need to be validated in children with HSPN if we intend to
apply them in clinical practice or trials.
Conclusion
In conclusion, limited number of children with HSPN
and relatively short periods of follow-up increase the
Table 4 Modified semiquantitative classification (according to
ref. [30])
Modified SQC Description Score
Glomerular changes
Lobulation Active 0 - 1a
Mesangial proliferation Active 0 - 1a
Crescents
Cellular Active 0 - 3b
Fibrous Chronic 0 - 3b
Adhesions Chronic 0 - 3b
Fibrinous thrombosis Active 0 - 3b
Global sclerosis Chronic 0 - 3b
Segmental sclerosis Chronic 0 - 2c
Tubular changes
Thickening of the
basement membrane
Chronic 0 - 1a
Complete atrophy Chronic 0 - 1a
Tubular dilatation Active 0 - 1a
Interstitial changes
Fibrosis Chronic 0 - 1a
Inflammation OR
periglomerular
inflammation
Chronic 0 - 1a
Capillary changes
Arteriosclerosis OR
arterial inflammation
Chronic 0 - 1a
Focal or diffuse mesangial
proliferation
0 for focal, 1 for diffuse
a0 = absent; 1 = present
b0 = 0% of glomeruli affected; 1 = 0–5% of glomeruli affected; 2 = 5–10% of
glomeruli affected; 3= > 10% of glomeruli affected
c0 = 0% of glomeruli affected; 1 = 0–5% of glomeruli affected; 2= > 5% of
glomeruli affected
Reproduced with permission from Springer Nature©
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need for multicenter multinational prospective studies
with joint collaboration between pediatric rheumatolo-
gists and nephrologists. It is necessary to raise awareness
of the fact that IGAV/HSP can cause renal complications
on the long term, even years after episode of purpura or
following resolution of urinary abnormalities [7, 9, 10].
Since, patients with IGAV/HSP without renal complica-
tions at diagnosis are followed by pediatric rheumatolo-
gists or nephrologists, shared efforts are needed to
prevent these patients from being lost during the
follow-up and to avoid overlooking the kidney disease. It
is therefore very important for future studies to observe
patients for a long period of time and at regular intervals
to include those who have a silent and subtle, insidious
progression of the disease as well as patients with
relapses [6]. Of great significance remains the need to
include in studies early stage patients to detect the risk
factors for progression of disease and for chronic renal
failure, and to avoid confounding factors caused by
treatment and selection bias by including patients with
severe renal impairment [17, 46]. Particular attention
needs to be devoted to strengthening the cooperation of
pediatric rheumatologists, pediatric nephrologists and
nephropathologists in different centers aiming at facili-
tating international exchange of knowledge and data.
Consequently, it is of crucial importance that pediatric
rheumatologists are also involved in validation of histo-
logical classifications in children with HSPN.
Given the fact that not insignificant proportion of the
total number of patients with IGAV/HSP will develop
renal impairment, we hope that the efforts for finding
proper histological classification in HSPN will result in
success as has been the case with lupus nephritis.
Abbreviations
ESRD: End-stage renal disease; HSP: Henoch-Schönlein purpura;
HSPN: Henoch-Schönlein purpura nephritis; IgAV: IgA Vasculitis;
ISKDC: International Study of Kidney Disease in Children; SQC: Modified
semiquantitative classification
Acknowledgements
None.
Funding
No funds to declare.
Availability of data and materials
Not applicable.
Authors’ contributions
All authors contributed to the writing of this report. SO was senior author and
MJ was leading author. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Table 5 Use of the ISKDC, the Oxford and other histological classifications for HSPN in different continents
Continent/Region ISKDC classification
Authors, ref.
Oxford classification
Authors, ref.
Other classifications
Name of classification, authors, ref.
Europe Koskela et al. 2017 [30]
Soylemezoglu et al. 2009 [21]
Lucas Garcia et al. 2009 [47]
Mizerska-Wasiak et al. 2018 [41]
Gülhan et al. 2015 [42]
Calvo-Río et al. 2013 [43]
Modified semiquantitative classification
Koskela et al. 2017 [30]
Local pathological scoring
Mohey et al. 2013 [48]
Pillebout et al. 2002 [49]
The classification developed by Heaton
Altugan et al. 2009 [50]
Classification according to Emancipator
Rauta et al. 2002 [51]
Coppo et al. 1997 [13]
North America Tarshish et al. 2004 [31] N/A The classification adapted from Andreoli and Bergstein
Foster et al. 2000 [52]
The classification developed by Heaton
Heaton et al. 1977 [53]
Meadow’s classification
Meadow et al. 1972 [54]
Latin America Buscatti et al.
2018 [55]
Fuentes et al.
2014 [56]
de Almeida et al. 2007 [57]
N/A N/A
Asia Inagaki et al. 2018 [44]
Fu et al. 2016 [58]
Lim et al. 2016
[25]
Inagaki et al. 2018 [44]
Xu et al. 2018 [17]
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Kanai et al. 2011 [59]
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Africa Naija et al. 2012 [60] N/A Histologic classification of Haas
Mitchell et al. 2010 [61]
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